Melanoma News and Research

Latest Melanoma News and Research

Scientists develop "electronic skin" for earlier identification of breast cancer

For detecting cancer, manual breast exams seem low-tech compared to other methods such as MRI. But scientists are now developing an "electronic skin" that "feels" and images small lumps that fingers can miss.

11 Sep 2014

Merck's Keytruda gets FDA approval for treatment of malignant melanoma

The recent approval of Merck & Co.'s Keytruda by the U.S. Food and Drug Administration for the treatment of malignant melanoma is a significant milestone for Merck & Co. and for the oncology immunotherapy drug market. Decision Resources Group anticipates the launch of Keytruda as the first anti-PD-1 immunotherapy in the United States for treatment of advanced and unresectable malignant melanoma.

10 Sep 2014

Study evaluates impact of myPath Melanoma diagnostic test

Myriad Genetics, Inc. today presented results from a pivotal clinical utility study of the Myriad myPath- Melanoma test at the 2014 College of American Pathologists (CAP) annual meeting in Chicago, Ill.

10 Sep 2014

Ortho-oncology team successfully adapts shoulder surgical aid

An ortho-oncology team at Dartmouth-Hitchcock Norris Cotton Cancer Center successfully adapted a shoulder surgical aid (the Spider Limb Positioner) to conduct a left hip disarticulation on a melanoma patient as described in a case report published online in Medical Devices.

9 Sep 2014

New immuno-oncology drug helps body's own immune system to fend off cancer

According to an August 25 Reuters report, the U.S. Food and Drug Administration is likely to approve Merck & Co.'s highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline.

8 Sep 2014

Soligenix acquires novel orphan drug candidate for treatment of CTCL

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the acquisition of a novel orphan drug candidate, known as SGX301 (synthetic hypericin).

8 Sep 2014

New cancer drug renews debate about costs

The drug Opdivo, which went on sale in Japan this week, costs an average of $143,000 per patient, The Wall Street Journal reports.

5 Sep 2014

Keytruda drug gets FDA approval for treatment of advanced melanoma

The U.S. Food and Drug Administration today approved a new immunotherapy drug to treat advanced melanoma, signaling a paradigm shift in the way the deadly skin cancer is treated.

5 Sep 2014

New actinic keratoses data presented at the 15th World Congress of Cancers of the Skin

New data from the international FIELD Study Repeat presented today at the 15th World Congress of Cancers of the Skin (WCCS) in Edinburgh, Scotland, demonstrate initial treatment with Picato® (ingenol mebutate gel) 0.015% is efficacious in treating actinic keratoses (AK) and, when followed by a repeat cycle for persistent and newly emerging AKs, this efficacy is further increased.1 The data also confirm two treatment cycles of Picato® are well tolerated by patients.2

4 Sep 2014

Ascend Biopharmaceuticals provides update on clinical trial program for lead immunotherapy products

Ascend Biopharmaceuticals, a Melbourne-based immunotherapy company, has released an update on the clinical trial pipeline for its lead immunotherapy products treating basal cell carcinoma (BCC) and breast cancer.

4 Sep 2014

First Edition: September 4, 2014

Today's headlines include reports about a new government report that predicts a rebound in national health spending.

4 Sep 2014

Pacific Edge signs agreement with SCPMG to evaluate Cxbladder User Program

Pacific Edge Ltd, a cancer diagnostics company, has signed an agreement with Southern California Permanente Medical Group (SCPMG) to research its User Program to evaluate its bladder cancer technology Cxbladder within the clinical settings of Kaiser Permanente's health care network.

3 Sep 2014

Amgen seeks EMA approval for marketing talimogene laherparepvec

Amgen today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) via the centralized procedure for talimogene laherparepvec seeking approval for the treatment of adults with melanoma that is regionally or distantly metastatic.

2 Sep 2014